Study guide
Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies
Key Takeaways Explain This Topic AI
Tumor lysis syndrome (TLS) produces hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia with acute kidney injury, and is most common with bulky, highly proliferative tumors such as Burkitt lymphoma and acute leukemias.
Rasburicase rapidly lowers uric acid but is contraindicated in G6PD deficiency because it can cause severe hemolysis and methemoglobinemia.
Hypercalcemia of malignancy is graded by corrected serum calcium: mild below 12 mg/dL, moderate 12 to 14 mg/dL, and severe above 14 mg/dL; aggressive isotonic saline is first-line therapy.
SIADH causes euvolemic dilutional hyponatremia; sodium must be corrected slowly (no more than about 8 mEq/L in 24 hours) to avoid osmotic demyelination.
Compare current labs against baseline and rate of change rather than judging a single value, because a rapidly rising potassium can be deadlier than a stable mild elevation.
Last updated: October 2026
Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies
Metabolic emergencies are heavily tested because they reward fast recognition and disciplined monitoring. Early symptoms look nonspecific: fatigue, nausea, poor intake, constipation, muscle cramps, headache, confusion, or falling urine output. The skilled RN connects these findings to diagnosis, treatment timing, renal function, hydration, and recent laboratory values.
Tumor Lysis Syndrome
Tumor lysis syndrome (TLS) occurs when malignant cells break down rapidly and dump intracellular contents into the blood. It is most associated with acute leukemias, Burkitt and other high-grade lymphomas, bulky disease, high white counts, high chemosensitivity, and pre-existing renal impairment , typically 12 to 72 hours after starting cytotoxic therapy (occasionally spontaneously before treatment).
- Lab change Direction Nursing concern
- Potassium High Dysrhythmia, cardiac arrest, peaked T waves
- Phosphorus High Binds calcium; renal injury
- Calcium Low (secondary) Tetany, seizures, prolonged QT, cramps
- Uric acid High Crystal nephropathy, acute kidney injury
- Creatinine Rising Falling clearance worsens every value above
Prevention and management include aggressive IV hydration, strict intake and output, daily weights, telemetry for high-risk patients, and frequent labs. Allopurinol blocks new uric acid formation, while rasburicase enzymatically degrades existing uric acid for high-risk patients. A high-stakes safety point: rasburicase is contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency because it precipitates hemolysis and methemoglobinemia. Do not give calcium for asymptomatic hypocalcemia in TLS unless directed - calcium-phosphate precipitation can worsen renal injury.
Hypercalcemia of Malignancy
Hypercalcemia is the most common metabolic emergency in cancer. Mechanisms include tumor secretion of parathyroid hormone-related peptide (PTHrP) (most cases, often squamous cell cancers), osteolytic bone metastases, and myeloma. Always use the corrected calcium for low albumin: add 0.8 mg/dL to the measured calcium for every 1.0 g/dL the albumin is below 4.0 g/dL. Severity grading drives urgency:
- Corrected calcium Severity Typical action
- Below 12 mg/dL Mild Hydration, treat the malignancy
- 12 to 14 mg/dL Moderate IV saline; bisphosphonate
- Above 14 mg/dL Severe Aggressive saline, calcitonin, admit
Classic symptoms follow the mnemonic "stones, bones, groans, thrones, and psychiatric overtones": kidney stones, bone pain, abdominal groans (constipation, nausea), polyuria (thrones), and confusion. The electrocardiogram shows a shortened QT interval . First-line therapy is aggressive isotonic saline to restore volume; calcitonin works within 4 to 6 hours and lasts about 2 days, as a bridge; a bisphosphonate (zoledronic acid) begins working in 2 to 3 days and its effect lasts 2 to 4 weeks, and denosumab , which is not cleared by the kidneys, is another option. Monitor for fluid overload in cardiac or renal patients, and never use loop diuretics until the patient is volume-replete.
SIADH and Hyponatremia
Syndrome of inappropriate antidiuretic hormone (SIADH) causes water retention and euvolemic, dilutional hyponatremia , classically with small cell lung cancer but also CNS disease, certain drugs (vincristine, cyclophosphamide, cisplatin), pain, and nausea. Labs show low serum sodium and serum osmolality with inappropriately concentrated urine (high urine sodium and osmolality). Symptoms track the sodium level and its speed of fall: headache, nausea, and cramps early; seizures, coma, and respiratory arrest with severe or rapid drops.
Implement seizure and fall precautions, frequent neuro checks, strict intake and output, and daily weights.
Apply fluid restriction only as ordered (often 800 to 1000 mL/day) and explain it clearly, since thirsty or confused patients undermine it.
Hypertonic (3%) saline is reserved for severe symptomatic hyponatremia; vasopressin antagonists (vaptans) may be used.
Correct sodium slowly - no more than about 8 mEq/L in 24 hours. Overly rapid correction risks osmotic demyelination syndrome (central pontine myelinolysis), a devastating, often irreversible neurologic injury. Never encourage unsupervised salt loading.
Escalation, Education, and Monitoring Patterns
Escalate urgently for seizure, new confusion, severe weakness, tetany, chest pain, palpitations, syncope, oliguria, or marked lab abnormalities. Use teach-back so high-risk patients know why labs are checked frequently, why hydration and urine measurement matter, and exactly which number to call. The core monitoring discipline is to trend against baseline and rate of change : a potassium still within range but climbing fast is more dangerous than a stable mild elevation, and for SIADH a new neurologic change is the warning that the sodium is now affecting the brain.
Worked Examples and Handoff
Work an example for each syndrome. In TLS, a patient with bulky Burkitt lymphoma starting chemotherapy reports muscle twitching, and labs show potassium 6.2, phosphorus 7.5, calcium 7.0, uric acid 11, and creatinine rising from 0.9 to 1.6. This is full-blown TLS - escalate, place on telemetry for the hyperkalemia, hold any potassium-containing fluids, anticipate rasburicase, and do not push calcium for the asymptomatic hypocalcemia.
In hypercalcemia, an older adult with breast cancer presents with confusion, constipation, and a corrected calcium of 14.5; this severe level needs aggressive isotonic saline, calcitonin as a bridge, and a bisphosphonate, with fall precautions for the altered mentation. In SIADH, a small cell lung cancer patient with a sodium of 116 and a new headache needs seizure precautions, ordered fluid restriction, and slow correction.
Handoff for any metabolic emergency should include the suspected syndrome, the most recent labs with their rate of change, fluids or fluid restriction ordered, medications given, telemetry and seizure-precaution status, and the family teaching completed. The recurring exam theme is that the nurse who trends values and links them to the diagnosis and treatment timing catches these emergencies before the patient codes, seizes, or goes into renal failure.